APA (7th ed.) Citation

Ferrante, M., D'Haens, G., Jairath, V., Danese, S., Chen, M., Ghosh, S., . . . Sands, B. E. (2024). Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: A phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet, 404(10470), 2423. https://doi.org/10.1016/S0140-6736(24)01762-8

Chicago Style (17th ed.) Citation

Ferrante, Marc, et al. "Efficacy and Safety of Mirikizumab in Patients with Moderately-to-severely Active Crohn's Disease: A Phase 3, Multicentre, Randomised, Double-blind, Placebo-controlled and Active-controlled, Treat-through Study." Lancet 404, no. 10470 (2024): 2423. https://doi.org/10.1016/S0140-6736(24)01762-8.

MLA (9th ed.) Citation

Ferrante, Marc, et al. "Efficacy and Safety of Mirikizumab in Patients with Moderately-to-severely Active Crohn's Disease: A Phase 3, Multicentre, Randomised, Double-blind, Placebo-controlled and Active-controlled, Treat-through Study." Lancet, vol. 404, no. 10470, 2024, p. 2423, https://doi.org/10.1016/S0140-6736(24)01762-8.